Matt Hayden Joins Luventix Advisory Board
Luventix, a leading innovator in Intelligent Disease Diagnostics, is pleased to announce that Matt Hayden has joined its Advisory Board.
Matt Hayden is a seasoned investor and strategic advisor with extensive experience in investment management, corporate communications, and socially responsible investing. As the manager of Sea Purity Investments, his first-generation family office, Matt employs a fundamental, multi-strategy approach aimed at producing positive, long-term absolute returns. His investment portfolio spans both private and public companies across multiple industries with a typical investment horizon of 2-5 years, with approximately 30% allocated to socially responsible companies.
Previously, Matt founded and served as Chairman of MZ North America, the U.S. division of MZ Group, the world's largest independent investor relations and corporate communications firm. Under his leadership, the firm provided investor and corporate communications services to over 200 public companies, successfully raising over $10 billion in growth capital.
"We are excited to welcome Matt Hayden to our Advisory Board," said George Holmes, CEO of Luventix. "His deep expertise in investment management, strategic advisory, and corporate communications will be invaluable in driving our continued growth and market expansion. Like us, he believes one of the best ways to effectuate meaningfully improved healthcare outcomes is to have widely available, simple and cost effective screening for many cancers and diseases."
About Luventix:
Luventix is a medical diagnostics company utilizing a simple, non-invasive urine test to detect and diagnose diseases through metabolomics modeling. By leveraging proprietary advanced machine learning (ML) modeling techniques, Luventix has the unique ability to analyze data and pinpoint disease-specific signatures within a Digital Twin, bridging the gap between diagnostics and therapeutics, revolutionizing clinical trial recruitment, and enabling companion diagnostics as an integral endpoint.
With a commitment to innovation, collaboration, and excellence, Luventix is redefining industry standards and making a meaningful impact on healthcare outcomes. By combining cutting-edge technology with strategic partnerships, Luventix aims to transform the landscape of personalized medicine and accelerate the delivery of life-changing solutions. For more information, please visit www.luventix.com.
Media Contact:
